Recent Company News

• 03:18 PM ET Jun 12, 2026
  

  Roche confirms FDA approval for Ventana PTEN approval for prostate cancer companion Dx (CHF 330.00, 0.00)

• 02:49 PM ET Jun 12, 2026
  

  Follow-up: FDA approves Truqap and a companion diagnostic for mHSPC (13462.0000p, 0)

• 08:43 AM ET Jun 12, 2026
  

  Disc Medicine presents clinical updates on DISC-0974, bitopertin, and DISC-3405 at 2026 EHA Annual Meeting ($68.08, 0.00)

• 03:09 AM ET Jun 12, 2026
  

  AbbVie presents new data from CLL14 trial of venetoclax at EHA 2026 Congress ($224.77, 0.00)

• 02:51 AM ET Jun 12, 2026
  

  Chugai Pharmaceutical files additional indication application for Tecentriq as maintenance therapy (¥7450.0000, 0)

• 05:50 PM ET Jun 08, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:57 AM ET Jun 11, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 01:04 AM ET Jun 11, 2026
  

  FDA grants Priority Review for Roche's Tecentriq for certain type of stage III colon cancer (CHF 323.90, 0.00)

• 01:02 AM ET Jun 11, 2026
  

  Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies (CHF 323.90, 0.00)